Abstract
Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”: Annals of Oncology 2020; 31, suppl.4: S472 (abstr. 540P)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have